The biotech Gilead Sciences has been the best-performing healthcare stock in the S&P 500 by far over the past 12 months. Its ...

(Nasdaq: GILD) announced today its first quarter 2025 results of operations. "Gilead had a strong start to the year driven by ...

Gilead Sciences on Thursday reported slightly higher-than-expected quarterly earnings on flat revenue, as higher sales of ...

Gilead Sciences releases its first-quarter results after Thursday's closing bell. Here's a look at the details from the report.

(GILD) on Thursday reported first-quarter earnings of $1.32 billion. The Foster City, California-based company said it had net income of $1.04 per share. Earnings, adjusted for costs related to ...

WARNING: The following story contains spoilers about the fifth episode of The Handmaid's Tale's sixth and final season, ...

"The Handmaid's Tale" may be coming to an end, but the world of Gilead is not with a sequel, "The Testaments," in production ...

Gilead Sciences said a combination of its cancer drug Trodelvy and Merck’s Keytruda delayed the growth of tumors in women ...

The cast of The Handmaid's Tale visits WIRED to answer the 50 most searched for questions about the show as it enters its ...

In the first phase 3 trial to show the superiority of a TROP2-targeted antibody-drug conjugate and an immunotherapy agent in ...